Enhancing glioma-specific drug delivery through self-assembly of macrophage membrane and targeted polymer assisted by low-frequency ultrasound irradiation

• Published in: Materials today bio 2024-06, Vol.26, p.101067-101067, Article 101067
• Main Authors: Lin, Junqing, Lin, Zhenhu, Liu, Leilei, Lin, Wenjin, Xie, Xiaodong, Zhang, Xiujuan
• Format: Article
• Language: English
• Subjects: Bone marrow-derived macrophage membrane; Glioma; Low-frequency ultrasound irradiation; Targeted drug delivery; Temozolomide
• ISSN: 2590-0064; 2590-0064
• DOI: 10.1016/j.mtbio.2024.101067

The blood-brain Barrier (BBB), combined with immune clearance, contributes to the low efficacy of drug delivery and suboptimal treatment outcomes in glioma. Here, we propose a novel approach that combines the self-assembly of mouse bone marrow-derived macrophage membrane with a targeted positive charge polymer (An-PEI), along with low-frequency ultrasound (LFU) irradiation, to achieve efficient and safe therapy for glioma. Our findings demonstrate the efficacy of a charge-induced self-assembly strategy, resulting in a stable co-delivery nanosystem with a high drug loading efficiency of 44.2 %. Moreover, this structure triggers a significant release of temozolomide in the acidic environment of the tumor microenvironment. Additionally, the macrophage membrane coating expresses Spyproteins, which increase the amount of An-BMP-TMZ that can evade the immune system by 40 %, while LFU irradiation treatment facilitates the opening of the BBB, allowing for enormously increased entry of An-BMP-TMZ (approximately 400 %) into the brain. Furthermore, after crossing the BBB, the Angiopep-2 peptide-modified An-BMP-TMZ exhibits the ability to selectively target glioma cells. These advantages result in an obvious tumor inhibition effect in animal experiments and significantly improve the survival of glioma-bearing mice. These results suggest that combining the macrophage membrane-coated drug delivery system with LFU irradiation offers a feasible approach for the accurate, efficient and safe treatment of brain disease. [Display omitted] •An-BMP-TMZ exhibits excellent biocompatibility, circulation time and safety.•LFU irradiation significantly enhanced the accumulation of An-BMP-TMZ in the brain.•An-BMP-TMZ exhibits selectively target GBM cells after accumulation in the brain.•An-BMP-TMZ demonstrates excellent safety to mice.